centchroman has been researched along with Ovarian Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattacharjee, A; Datta, D; Hasanain, M; Kathuria, M; Mitra, K; Sarkar, J; Singh, A | 1 |
| Bauer, NA; Bell, MC; Chauhan, SC; Ebeling, MC; Halaweish, F; Jaggi, M; Khan, S; Kopel, L; Maher, DM; Nordquist, JL; Singh, MM | 1 |
2 other study(ies) available for centchroman and Ovarian Neoplasms
| Article | Year |
|---|---|
Ormeloxifene-induced unfolded protein response contributes to autophagy-associated apoptosis via disruption of Akt/mTOR and activation of JNK.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzopyrans; Cell Line, Tumor; Cell Survival; Female; Heterografts; Humans; Mice; Neoplasm Transplantation; Ovarian Neoplasms; Signal Transduction; Treatment Outcome; Unfolded Protein Response | 2018 |
Ormeloxifene efficiently inhibits ovarian cancer growth.
Topics: Animals; Apoptosis; Benzopyrans; Blotting, Western; Cell Cycle; Cell Proliferation; Female; Flow Cytometry; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |